Shell Asset Management Co. Increases Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Shell Asset Management Co. increased its stake in Boston Scientific Corporation by 72.3%, owning 35,233 shares valued at approximately $3.78 million at the end of the second quarter.
• Boston Scientific reported a $0.75 EPS for the last quarter, exceeding analysts' estimates of $0.72, with a 22.8% year-over-year revenue growth.
• Research analysts have generally positive outlooks on Boston Scientific, with target price increases from several firms, including UBS raising it to $135.00 and Robert W. Baird to $128.00.

Shell Asset Management Co. lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 72.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,233 shares of the medical equipment provider's stock after buying an additional 14,779 shares during the quarter. Shell Asset Management Co.'s holdings in Boston Scientific were worth $3,784,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. HM Payson & Co. raised its stake in Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. IVC Wealth Advisors LLC grew its position in Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock valued at $236,000 after acquiring an additional 102 shares during the last quarter. Park Square Financial Group LLC grew its position in Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after acquiring an additional 103 shares during the last quarter. HHM Wealth Advisors LLC grew its position in Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after acquiring an additional 103 shares during the last quarter. Finally, Rise Advisors LLC grew its position in Boston Scientific by 13.9% during the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 103 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

NYSE:BSX opened at $95.86 on Wednesday. The stock has a market cap of $142.05 billion, a P/E ratio of 57.06, a price-to-earnings-growth ratio of 2.33 and a beta of 0.61. The firm's fifty day simple moving average is $102.53 and its 200 day simple moving average is $101.99. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the previous year, the business posted $0.62 EPS. The company's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird raised their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday, October 1st. UBS Group raised their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Weiss Ratings restated a "buy (b-)" rating on shares of Boston Scientific in a report on Saturday, September 27th. Finally, Truist Financial raised their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $120.71.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.